Showing results (1-10 of 193) with videos related to
Sort By:
Pageof 20
Current Opinion in Lipidology|November 21, 2002
HDL and triglyceride as therapeutic targetsJean-Charles Fruchart, Patrick DuriezDrugs of Today (Barcelona, Spain : 1998)|March 3, 2006
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolismJean-Charles Fruchart, Patrick DuriezCirculation|June 17, 2004
Atherogenic lipoprotein particles in atherosclerosisRafael Carmena, Patrick Duriez, Jean-Charles FruchartAtherosclerosis|July 18, 2002
Apolipoprotein A-II, HDL metabolism and atherosclerosisAnne Tailleux, Patrick Duriez, Jean-Charles Fruchart, et al.The American Journal of Clinical Nutrition|May 11, 2005
Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitisDidier Quilliot, Evelyne Walters, Jean-Paul Bonte, et al.Planta Medica|April 5, 2003
Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicityFrançoise Martin-Nizard, Sevser Sahpaz, Christophe Furman, et al.Clinical Science (London, England : 1979)|August 24, 2002
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cellsAbdelmejid Kandoussi, François Martin, Marc Hazzan, et al.The Journal of Pharmacy and Pharmacology|November 27, 2004
Natural phenylpropanoids inhibit lipoprotein-induced endothelin-1 secretion by endothelial cellsFrançoise Martin-Nizard, Sevser Sahpaz, Abdelmejid Kandoussi, et al.Circulation|June 17, 2004
New risk factors for atherosclerosis and patient risk assessmentJean-Charles Fruchart, Melchior C Nierman, Erik S G Stroes, et al.Cardiovascular Diabetology|October 6, 2017
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemiaJean-Charles FruchartPageof 20